Kyle Doherty

Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.

Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

As technology and cancer care continue to become intertwined at every level, there is an imperative need to effectively process and use vast amounts of data to provide the highest level of care for patients.

Physical function-related symptoms were prominent in the symptom burden of adult patients with myelofibrosis and moderate or severe thrombocytopenia, according to a retrospective analysis of the phase 3 PERSIST-2 study.

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

Nivolumab in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma.

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

Investigators are hoping to dramatically improve the platinum-resistant ovarian cancer treatment paradigm with the development of the first-in-class antibody-drug conjugate upifitamab rilsodotin.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended pembrolizumab for the treatment of adult patients with a variety of microsatellite instability-high or mismatch repair deficient tumors.

Muhammad Bilal Abid, MD, MRCP, discusses clinical takeaways regarding the standard use of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific T-cell engagers.

Efforts are underway to evaluate novel, durable treatment options for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the phase 1b/2 FELIX trial evaluating obecabtagene autoleucel, a novel, second-generation CAR T-cell therapy.

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

Patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation treated with maintenance olaparib who achieved long-term progression-free survival more often had homologous recombination deficiency-positive tumors compared with those who experienced a short-term PFS.

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

Investigators hope to address the need for additional treatment options for patients with class II or class III BRAF-altered disease with KIN-2787, a next-generation, orally available, potent, and selective small molecule inhibitor.

"If you stay at home too long, with too narrow a focus, you lose sight of what’s happening in the world."

The long-term dramatic effects of the COVID-19 pandemic on cancer research and patient care present several challenges but also future opportunities.

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Patients with cancer should be fully immunized against COVID-19, including third doses and/or any approved boosters.

Patient education in oncology can often be daunting and complicated for clinicians and patients.

Mirati Therapeutics and Verastem Oncology have entered a nonexclusive clinical collaboration to evaluate the combination of adagrasib plus VS-6766 for patients with non–small cell lung cancer harboring a KRAS G12C mutation who have progressed on a KRAS G12C inhibitor in a phase 1/2 trial.

Driven by the anticipated launches of 5 pipeline agents and the label expansions of currently marketed drugs, theHER2-postive breast cancer market is expected to experience low growth from 2020 to 2030.

Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.

Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.

Investigators hope to improve upon the efficacy and tolerability of androgens in the treatment of breast cancer with the October 13, 2021, initiation of the phase 3 ARTEST trial.

The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.